TY - JOUR T1 - RNA sequencing identifies a cryptic exon caused by a deep intronic variant in <em>NDUFB10</em> resulting in isolated Complex I deficiency JF - medRxiv DO - 10.1101/2020.05.21.20104265 SP - 2020.05.21.20104265 AU - Guy Helman AU - Alison G. Compton AU - Daniella H. Hock AU - Marzena Walkiewicz AU - Gemma R. Brett MGenCouns AU - Lynn Pais AU - Tiong Y. Tan AU - Ricardo De Paoli-Iseppi AU - Michael B. Clark AU - John Christodoulou AU - Susan M. White AU - David R. Thorburn AU - David A. Stroud AU - Zornitza Stark AU - Cas Simons Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/26/2020.05.21.20104265.abstract N2 - The diagnosis of mitochondrial disorders remains a challenging and often unmet need. We sought to investigate a sibling pair with suspected mitochondrial disease and a clinical presentation notable for global developmental delay, poor growth, sensorineural hearing loss, and brain MRI abnormalities, both with early death. Following uninformative exome and genome sequencing of the family quartet, RNA sequencing was pursued as an orthogonal testing strategy. RNA sequencing of fibroblasts from the older sibling identified the presence of a cryptic exon in intron 1 of NDUFB10, that included an in-frame stop codon. NDUFB10 encodes a subunit of mitochondrial OXPHOS complex I. Differential expression analysis relative to control samples suggested significantly decreased expression. The cryptic exon was found to contain a rare intronic variant, NM_004548.3:c.131-442G&gt;C, that was homozygous in both affected siblings and absent from population allele frequency databases. Immunoblot and quantitative proteomic analysis of fibroblasts from the older sibling revealed decreased abundance of complex I subunits associated with NDUFB10, providing evidence of isolated complex I deficiency. Biallelic variants in NDUFB10 have previously been reported in a single individual with infantile-onset mitochondrial disease. We present data implicating a deep intronic variant in NDUFB10 as the cause of mitochondrial disease in two further individuals. This variant results in loss of expression and overall destabilization of mitochondrial OXPHOS complex I and highlights the importance of RNA sequencing as a complementary diagnostic tool in patients undergoing genome-wide diagnostic evaluation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research conducted at the Murdoch Children's Research Institute was supported by the Victorian Government's Operational Infrastructure Support Program. This study was supported in part by the Leukodystrophy Flagship Massimo's Mission, funded by the Medical Research Future Fund (ARG76368). We acknowledge funding from the National Health and Medical Research Council (NHMRC Project Grants 1164479 to AGC, DRT, JC, DAS, 1140906 to DAS; NHMRC Fellowships 1072662 to MBC, 1140851 to DAS and 1155244 to DRT). DHH is supported by a Melbourne International Research Scholarship and the Mito Foundation PhD Top-up Scholarship. Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All research activities were performed under institutional ethics approval from The Royal Children's Hospital Melbourne (HREC/16/RCHM/150) and written informed consent was provided by both parents.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. ER -